MacroGenics
Rockville
About MacroGenics
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $275.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2019)
- Ticker: nasdaq:MGNX
- Website: macrogenics.com
- Phone: +1-3012515321
Industries & Categories
Biotechnology, Health Care, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/macrogenics-39258 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.